1674 - Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

FS

Fakhar Siddiqui, MD, MBA

Merck & Co., Inc.
Rahway, New Jersey, United States
JP

Jacqueline Pavia, MD

Regional Director
MSD Colombia, Bogota, Colombia.
Bogota, Distrito Capital de Bogota, Colombia
CD

Charles A. DeRyke, PharmD

Director
Merck Research Laboratories
Longwood, Florida, United States
Katherine Young, M.S. (she/her/hers)

Senior Principal Scientist
Merck
Rahway, New Jersey, United States
MM

Mary Motyl, Ph.D.

Distinguished Senior Principal Scientist
Merck
Rahway, New Jersey, United States
DS

Daniel F. Sahm, PhD

VP Global Microbiology Services & Chief Scientific Officer
IHMA
Schaumburg, Illinois, United States